Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9489610.26442/2075-1753_19.9.69-76ArticlesСтатьиReview ArticleUpdated international guidelines for the management of patients with osteoarthritis in 2016: focus on chondroitin sulfate, glucosamine and their combination (Theraflex®)Обновленные международные рекомендации 2016 г. по ведению больных остеоартрозом: фокус на хондроитин сульфат, глюкозамин и их комбинацию (препарат Терафлекс®)ChichasovaN. VЧичасоваНаталья Владимировна

д-р мед. наук, проф. каф. ревматологии ИПО

kafedrarheum@yandex.ruI. M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России15092017199VOL 19, NO9 (2017)ТОМ 19, №9 (2017)697628122021Copyright ©; 2017, Consilium MedicumCopyright ©; 2017, ООО "Консилиум Медикум"2017Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/94896

The article provides updated data on the international recommendations of the European Society in the field of studying the clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO) in 2016, which additionally takes into account the factors of unfavorable tolerability of paracetamol and other fast-acting symptom-modifying drugs. The data of domestic studies showing a reliable analgesic effect of a combination of chondroitin sulfate and glucosamine hydrochloride (Theraflex® preparation), which develops during the first 1-3 months of treatment and persists with prolonged use, are reflected. The data of the latest internationally controlled double-blind studies, which confirmed domestic data, and also showed the structural-modifying possibilities of combined use of these substances are given.

В статье приведены обновленные данные международных рекомендаций Европейского общества в области изучения клинических и экономических аспектов остеопороза и остеоартрита (ESCEO) 2016 г., в которых дополнительно учтены факторы неблагоприятной переносимости парацетамола и других быстродействующих симптом-модифицирующих препаратов. Отражены данные отечественных исследований, продемонстрировавших достоверный анальгетический эффект комбинации хондроитин сульфата и глюкозамина (препарат Терафлекс®), развивающийся в первые 1-3 мес лечения и сохраняющийся при длительном применении. Приведены данные последних международных контролируемых двойных слепых исследований, подтвердившие отечественные данные, а также показавшие структурно-модифицирующие возможности комбинированного использования этих субстанций.

osteoarthritisslow-acting symptom-modifying drugschondroitin sulfateglucosamineparacetamolstructural-modifying effectостеоартрозмедленнодействующие симптом-модифицирующие препаратыхондроитин сульфатглюкозаминпарацетамолструктурно-модифицирующее действиеBijlsma J.W, Berenbaum F, Lafeber F.P. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011; 377: 2115-26.Pereira D, Peleteiro D, Araujo J. et al. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthr Cartilage 2011; 19: 1279-85.Галушко Е.А., Большакова T.B., Виноградова И.Б. и др. Структура ревматических заболеваний среди взрослого населения России по данным эпидемиологического исследования (предварительные результаты). Научно-практическая ревматология. 2009; 1: 11-7.World Health Statistics 2012. Geneva: World Health Organization.Global, regional, and national incidence, prevalence, and year lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013; a systematic analysis for the Global Burden of Disease Study 2013. GBDS 2013. Collaborators. www.thelancet.comChen A, Gupte C., Akhtar K. et al. The Global Economic Cost of Osteoarthritis: How the UK Compares, Arthritis, 2012. http://www.hindawi.com/journals/arthritis/2012/698709Dawson J.I.LI, Limsell L, Zondervan K. et al. Impact of persistent hip or knee pain overall health status in elderly People: a longitudinal population study. Arthr Rheum 2005; 53: 368-74.Martin G, Balshaw R, Conaghan P. et al. Inadequate pain relief in knee osteoarthritis: an early look at the survey in osteoarthritis real world therapies (SORT). Eur J Pain 2011; 5 (Suppl. 1): 74.Van Dijk G.V, Veenhof C, Schelleviset S. et al. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMC Musculoskelet Disord 2008; 9.McAlindon T.E, Bannuru R.R, Sullivan M.C. et al. OARSI Guielines for the non-surgical management of knee osteoarthritis. Ostearthr Cartilage 2014; 22: 363-88.Wills A.K, Black R, Cooper R. et al. Life course body mass index and risk of knee osteoarthritis at the age of 53 years: evidence from 1946 British cohort study. Ann Rheum Dis 2012;71:655-60.Felson D.T. Osteoarthritis of knee. N. Engl J Med 2006; 354: 841-8.Mc Alindon T.E, Bannuru R.R, Sullivan M.C. et al. OARSI Guidelines for the non-surgical management of knee osteoarthritis. Ostearthr Cartilage 2014; 22: 363-88.Чичасова Н.В. Современные рекомендации по лечению остеоартроза. Consilium Medicum. 2016; 18 (2): 124-33. / Chichasova N.V. Current recommendations for the treatment of osteoarthritis. Consilium Medicum. 2016; 18 (2): 124-33. [in Russian]Bruyere O., Cooper C, Peletier J-P. et al. An algorithm recommendation for the management of knee jsteoarthritis in Europe and internationality: a report from a tack force of the European Society for Clinical and Ecomomic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Sem Arthr Rheum 2014; 44: 253-63.McAlindon T.E, Bannuru R.R, Sullivan M.C. et al. OARSI Guidelines for the non-surgical management of knee osteoarthritis. Ostearthr Cartilage 2014; 22: 363-88.Jordan K.M, Arden N.K, Doherty M. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145-55.Hochberg M.C, Altman R.D, April K.T. et al. American College of Rheumatology 2012 recommendation for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012; 64: 465-74.Zhang W., Moskowitz R.W, Nuki G. et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Ostearthr Cartilage 2007; 15: 981-1000.Zhang W., Moskowitz R.W, Nuki G. et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based expert consensus guidelines. Ostearthr Cartilage 2008; 16: 137-62.Zhang W., Nuki G., Moskowitz R.W.et al. OARSI recommendation for the management of hip and knee osteoarthritis, part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartilage 2010; 18: 476-99.Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике. М.: ИМА- Пресс, 2015.Murphy G, Lee M.H. What are the roles of metalloproteinases in cartilage and bone damage? Ann Rheum Dis 2005; 64: iv44-iv47.Bannuri R.R, Dasi U.R, McAlindon T.E. Reassessing the role of acetaminophen in osteoarthritis: a systematic review and meta-analysis. Osteoarthr Cartilage 2010; 18 (Suppl. 2): S250.Rahme E, Barcum A, Nedjar H. et al. Hospitalization for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec. Canada Hospitalization Risk for upper and lower GI events with NSAID and acetaminophen use. American J Gastroent 2008; 103: 872-82.Curhan G.C, Knight E.L, Rosner B.et al. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arc Intern Med 2004; 164: 1519-24.Forman J.P, Rimm E.B, Curhan G.C. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007; 167: 394-9.Curhan G.C, Willett W.C, Rosner B, Stampfer M.J. Frequency of analgesic use and risk of hypertension in younger women. Arc Inern Med 2002; 162: 2204-8.Roberts E, Delgado V, Nunes S. et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis 2016; 75: 552-9.Bruyere O, Cooper C, Pelletier J-P. et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis - From evidence-based medicine to the real-life setting. Semin Arthr Rheum 2016; 45: S3-S11.Delafuente J.C. Glucosamine in the treatment of osteoarthritis. Rheum Dis Clin North Am 2000;26:1-11.Houpt J.B, McMillan R. et al. Effect of treatment of glucosamine hydrochloride in the treatment of pain in osteoarthritis of the knee. J Rheum 1998; 25 (Suppl. 52): 8.Mazieres B., Combe B., Phan Van V et al. Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. J Rheum 2001; 28: 173-81.Hochberg M.C, Zhan M., Langenberg P. The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate. Curr Med Res Opin 2008; 24: 3029-35.Kahan A., Uebelhart D, DeVathaire F. et al. Long-term effects of chondroitin 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthr Rheum 2009; 60: 524-33.Wildi I.M, Raynauld J.P, Martel-Pelletier J. et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011; 70: 982-9.Reginster J.Y, Deroisy R, Rovati I.C. et al. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 367: 251-6.Pavelka K., Gatterova J, Olejarova M. et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomised, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113-23.Wandel S., Juni P., Tendal B. et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. Br Med J 2010; 341: c4675.McAlindon T.E, LaValley M.P, Gulin J.P, Felson D.T. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283:1469-75.Leeb B.F, Schweitzer H, Montag K, Smolen J.S. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000; 27: 205-11.Baici A, Bradamante P. Interaction between human leukocyte elastase and chondroitin sulfate. Chem Biol Interaction 1984; 51: 1-11.Lippielo L, Grande D. In vitro chondroprotection of glucosamine and chondroitin sulfate in a rabbit model of a OA and demonstration of metabolic synergy on chondrocyte in vitro. Ann Rheum Dis 2000; 59 (Suppl. 1): 266.Yaron I, Shirasi R, Judovich R, Yaron M. Chondroitin sulfate inhibits prostaglandin E2 production in synovial cell cultures and reverses IL-1 inhibition of cartilage synthesis. Ann Rheum Dis 2000; 59 (Suppl. 1): 265.Lippielo L, Woodword J, Karpman D. et al. Beneficial effect of cartilage structure modifying agents tested in chondrocyte and rabbit instability model osteoarthrosis. Arthr Rheum 1999; 42 (Suppl.): 256.Lippiello L. Collagen Synthesis in Tenocytes, Ligament Cells and Chondrocytes Exposed to a Combination of Glucosamine HCl and Chondroitin Sulfate. Evid Based Complement Alternat Med. 2007; 4 (2): 219-24.Clegg D.O, Reda D.J, Harris C.L. et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354 (8): 795-808.Лила А.М., Мазуров В.И., Шидловская О.В., Шостак М.С. Терафлекс в комплексной терапии остеоартроза коленных суставов и позвоночника (результаты клинического исследования). РМЖ. 2005; 13 (24): 1618-22.Алексеева Л.И., Беневоленская Л.И., Зайцева Е.М. Эффективность препарата Терафлекс у больных остеоартрозом коленных и тазобедренных суставов (открытое рандомизированное исследование). РМЖ. 2005; 13 (8): 525-7.Светлова М.С. Влияние длительной терапии Терафлксом на симптомы и качество жизни у больных с ранними стадиями гонартроза. Соврем. ревматология. 2010; 2: 46-52Алексеева Л.И. результаты открытого сравнительного рандомизированного исследования эффективности и безопасности двух схем лечения препаратом Терафлекс у пациентов с остеоартрозом коленного сустава. Клиническое исследование. РМЖ. 2008; 16 (5): 316-9.Алексеева Л.И., Шарапова Е.П. Комбинированные симптоматические препараты замедленного действия в терапии остеоартроза. РМЖ. 2009; 17 (4): 1-5.Поворознюк В.В. Эффективность препарата Терафлекс Адванс в лечении болевого синдрома при остеоартрозе коленных суставов. Здоров'я Украины. 2007; 1-3Hochberg M.C, Martel-Pelletier J, Monfort J. et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 2016; 75: 37-44.Fransen M, Agaliotis M, Nairin L. et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis 2014; 73: 1-8. DOI: 10.1136/annrheumdis-2013-203954Martin-Pelletier J, Roubille C, Abram F. et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis 2015; 74: 547-56.Алексеева Л.И. Рекомендации по лечению остеоартроза. www.rheumarolog.ru